The TWILIGHT-SYNERGY subgroup analysis demonstrated comparable safety and efficacy of the bioabsorbable polymer (BP) everolimus-eluting stent versus durable polymer DES in high-risk patients undergoing PCI, as well as advantage of 3 months DAPT followed by ticagrelor monotherapy, as compared with long term DAPT, in term of ischemic and hemorrhagic profile irrespective of DES type. This study confirms and extends previous evidences about safety profile of BP-DES and short term DAPT also in high risk patients. Future studies should focus on further technological improvements and on particular clinical setting where these devices could prove potential superiority.
© 2021 Wiley Periodicals LLC.